SequelSEC

Turn Therapeutics Inc. TTRX

Pharmaceutical Preparations · CIK 0002023016 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$6.98M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.87x15th

Turn Therapeutics Inc. (TTRX) reported net income of -$8.45M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Turn Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Turn Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$6.98M
Net income-$8.45M
Research & development$778.13K
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$6.20M
Selling & marketingUnavailable

Balance

Turn Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$9.95M
Total assets$16.96M
Current assets$10.43M
Total liabilities$16.27M
Current liabilities$8.76M
Total equity incl. NCI$686.89K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$6.06M
Accounts payableUnavailable

Cash flow

Turn Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$4.32M
Capital expendituresUnavailable
Investing cash flow-$139.26K
Financing cash flow$11.56M
Net change in cashUnavailable
Stock-based compensation$995.53K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Turn Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio1.19x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equity8.83x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TTRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.